Literature DB >> 18570709

Evaluation of prostate cancer characteristics in four populations worldwide.

Charnita M Zeigler-Johnson1, Hanna Rennert, R Devi Mittal, Mohamed Jalloh, Rajeev Sachdeva, S Bruce Malkowicz, Anil Mandhani, B Mittal, Serigne M Gueye, Timothy R Rebbeck.   

Abstract

INTRODUCTION: Prostate cancer is common around the world, but rates of advanced disease differ substantially by race and geography. Although a major health issue, little is known about prostate cancer presentation in West Africa and India compared to the United States (US).
OBJECTIVE: The aim of this study was to compare prostate tumor characteristics in four populations of men from the US, Senegal and India.
MATERIALS AND METHODS: We recruited prostate cancer patients from four hospital-based populations. The sample included 338 African-Americans, 1265 European-Americans, 122 Asian Indians, and 72 Senegalese. Questionnaire and medical record data were collected on each participant.
RESULTS: We found significant differences in age at diagnosis, BMI, and PSA levels across the groups. Senegalese and Indian men had a higher probability of high stage (T3/T4) disease compared to US men. Gleason grade was significantly higher in Asian Indians compared to other populations. African-Americans, Senegalese, and Asian Indians had a significantly higher probability of metastatic disease compared to European Americans. The odds ratios (OR) for metastasis were consistently higher in Asian Indians compared to American cases. As only 19/72 Senegalese were assessed for metastasis, OR could not be determined for metastasis.
CONCLUSIONS: These results suggest that there are significant geographical and ethnic differences in the presentation of prostate cancer. Men in developing countries tend to present with advanced disease compared to US men. Identifying risk factors for advanced disease may help to decrease the rate of poor prostate cancer outcomes and associated mortality worldwide.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18570709      PMCID: PMC3072889     

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  34 in total

Review 1.  Cancer burden in the year 2000. The global picture.

Authors:  D M Parkin; F I Bray; S S Devesa
Journal:  Eur J Cancer       Date:  2001-10       Impact factor: 9.162

2.  The prevalence of high-grade prostatic intraepithelial neoplasia in surgical resection specimens: an Indian experience.

Authors:  Sangeeta B Desai; Anita M Borges
Journal:  Cancer       Date:  2002-05-01       Impact factor: 6.860

3.  International trends in prostate-cancer mortality in the "PSA ERA".

Authors:  S E Oliver; M T May; D Gunnell
Journal:  Int J Cancer       Date:  2001-06-15       Impact factor: 7.396

4.  Prostate cancer risk is three-fold higher among men, aged 50-64, of African descent compared with men of Asian-Indian descent in Trinidad and Tobago.

Authors:  Clareann H Bunker; Alan L Patrick; Gloria Maharaj; Hillary A Keenan; Sham Ramnarine; Andrew Belle; Jean Robert Richard; Rajiv Dhir
Journal:  Ethn Dis       Date:  2002       Impact factor: 1.847

5.  African American men and hereditary/familial prostate cancer: Intermediate-risk populations for chemoprevention trials.

Authors:  I J Powell; F L Meyskens
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

6.  The glutathione S-transferase-mu and -theta genotypes in the etiology of prostate cancer: genotype-environment interactions with smoking.

Authors:  S N Kelada; S L Kardia; A H Walker; A J Wein; S B Malkowicz; T R Rebbeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-12       Impact factor: 4.254

7.  Benign prostatic hyperplasia and prostate carcinoma in native Africans.

Authors:  D Dawam; A H Rafindadi; G D Kalayi
Journal:  BJU Int       Date:  2000-06       Impact factor: 5.588

8.  The changing pattern of prostate cancer in Nigerians: current status in the southeastern states.

Authors:  Paul D Ekwere; S N Egbe
Journal:  J Natl Med Assoc       Date:  2002-07       Impact factor: 1.798

9.  Prostate cancer characteristics in a multiracial community.

Authors:  Vincent Ravery; Sébastien Dominique; Vincent Hupertan; Sami Ben Rhouma; Marianne Toublanc; Liliane Boccon-Gibod; Laurent Boccon-Gibod
Journal:  Eur Urol       Date:  2007-04-23       Impact factor: 20.096

10.  Differences in prognostic factors and survival among White men and Black men with prostate cancer, California, 1995-2004.

Authors:  Anthony S Robbins; Daixin Yin; Arti Parikh-Patel
Journal:  Am J Epidemiol       Date:  2007-04-09       Impact factor: 4.897

View more
  30 in total

1.  Anti-tumor activity of curcumin against androgen-independent prostate cancer cells via inhibition of NF-κB and AP-1 pathway in vitro.

Authors:  Shuanglin Liu; Zhihua Wang; Zhiquan Hu; Xing Zeng; Youyuan Li; Yaowu Su; Chuanhua Zhang; Zhangqun Ye
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-08-07

2.  Low expression of microRNA-30c promotes prostate cancer cells invasion involved in downregulation of KRAS protein.

Authors:  Jun Zhang; Xilong Wang; Yangyun Wang; Ruixian Peng; Zhiyuan Lin; Yang Wang; Bo Hu; Jifeng Wang; Guowei Shi
Journal:  Oncol Lett       Date:  2017-05-12       Impact factor: 2.967

3.  Diagnostic performance of microRNAs expression in prostate cancer.

Authors:  Qinfeng Yang; Yushan Zheng; Dequan Zhu
Journal:  Tumour Biol       Date:  2014-07-25

4.  Discrimination of prostate carcinoma from benign prostate tissue fragments in vitro by estimating the gross biochemical alterations through Raman spectroscopy.

Authors:  Landulfo Silveira; Kátia Ramos M Leite; Fabricio Luiz Silveira; Miguel Srougi; Marcos Tadeu T Pacheco; Renato Amaro Zângaro; Carlos Augusto Pasqualucci
Journal:  Lasers Med Sci       Date:  2014-03-12       Impact factor: 3.161

Review 5.  Analysis of Tumor Biology to Advance Cancer Health Disparity Research.

Authors:  Cheryl J Smith; Tsion Z Minas; Stefan Ambs
Journal:  Am J Pathol       Date:  2017-11-11       Impact factor: 4.307

6.  MD-miniRNA could be a more accurate biomarker for prostate cancer screening compared with serum prostate-specific antigen level.

Authors:  Dong Xue; Cui-Xing Zhou; Yun-Bo Shi; Hao Lu; Xiao-Zhou He
Journal:  Tumour Biol       Date:  2015-01-05

Review 7.  Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies.

Authors:  Vasanthakumar Sekar; Debapriya Ghosh Mehrotra; Biswanath Majumder
Journal:  Indian J Surg Oncol       Date:  2016-12-15

8.  TRUS Biopsy Yield in Indian Population: A Retrospective Analysis.

Authors:  Sunil Raghunath Patil; Prakash Wamanrao Pawar; Ajit Somaji Sawant; Akshay Vijay Patil; Sayalee Suryabhan Narwade; Shankar Tanaji Mundhe; Abhishek Jaysukhbhai Savalia; Ashwin Sunil Tamhankar
Journal:  J Clin Diagn Res       Date:  2017-02-01

9.  CLINICO-PATHOLOGICAL FEATURES OF PROSTATE CANCER AT THE UNIVERSITY HOSPITAL YALGADO OUEDRAOGO, OUAGADOUGOU, BURKINA FASO.

Authors:  B Kirakoya; P P Hounnasso; A K Pare; A B Mustapha; B Zango
Journal:  J West Afr Coll Surg       Date:  2014 Oct-Dec

Review 10.  Biological determinants of health disparities in prostate cancer.

Authors:  Damali N Martin; Adrienne M Starks; Stefan Ambs
Journal:  Curr Opin Oncol       Date:  2013-05       Impact factor: 3.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.